Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Piotr Ponikowski,
Dr. Bertram Pitt,
Read the ESC Press release
Presenter | see Discussant report
Bertram Pitt (United States of America)Presentation slides
List of Authors: Pitt Bertram, McMurray John, Krum Henry, van Veldhuisen Dirk J, Swedberg Karl, Shi Harry, Vincent John, Pocock Stuart, Zannad Faiez
Purpose : In chronic moderate-to-severe HF and post MI CHF with LVSD, aldosterone antagonists have been shown to improve survival. More recently the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF) demonstrated a reduction of the primary endpoint which was a composite of death from cardiovascular causes and hospitalization for heart failure (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.54 to 0.74; P<0.001) in patients with chronic systolic HF in NYHA class II. It is not known however whether eplerenone can improve outcomes in mildly symptomatic patients, especially in the high risk groups defined as age ≥ 75 years, LVEF<30%, eGFR<60 ml/min/1.73 m2, diabetes and patients with low BP (<median). Methods : We randomly assigned 2737 patients with New York Heart Association class II heart failure and an ejection fraction of no more than 35% to receive eplerenone (up to 50 mg daily) or placebo, in addition to recommended therapy and analyzed prespecified subgroups of patients with high risk. After the premature stopping of enrollment into the trial due to efficacy (mean FU 21 months) patients had an additional follow-up of up to 7 months. Results and Conclusions: In the subgroup of patients ≥ 75 years the HR for the primary endpoint was 0.66 (95%CI 0.49-0.88; p=0.0044). In patients with a LVEF<30% the HR was 0.65 (95%CI0.53-0.78; p<0.0001); in those with type-2 diabetes the HR was 0.54 (95%CI 0.42-0.70; p<0.0001), in patients with a eGFR <60 ml/min/1.73 m2 the HR was 0.62 (95%CI 0.49-0.79; p<0.0001) and in patients with a systolic BP < the median of 123 mmHg the HR was 0.62 (95%CI 0.51-0.79; p<0.0001). Additionally, in these five sub-groups, the secondary endpoints of all-cause hospitalization and HF hospitalization achieved statistically significant relative risk reductions for the eplerenone group compared to the placebo group (p<0.01). In each of the high risk sub-groups evaluated, patients receiving eplerenone had a significant increase in the incidence of hyperkalaemia (K+ > 5.5 mmol/l). However, there was no significant increase in serious hyperkalemia (K+ > 6.0 mmol/l), hyperkalaemia leading to drug discontinuation, hospitalization for hyperkalemia, or hospitalization for worsening renal function. The beneficial effect of eplerenone on the primary endpoint of the EMPHASIS trial (death from cardiovascular causes and hospitalization for heart failure) remained significant over an additional follow-up of up to 7 months (HR 0.66; 95%CI 0.57-0.77; p<0.0001). Conclusions: The consistency of the efficacy and safety of eplerenone in addition to standard therapy on pre-specified high-risk subgroups and the persistence of a significant beneficial effect on the primary endpoint (cardiovascular mortality or hospitalization for heart failure) over an additional up-to 7 months of follow-up on double-blind therapy in conjunction with prior beneficial results from EPHESUS presents compelling evidence for the use of eplerenone in patients with systolic heart failure and mild symptoms.
Discussant | see Presenter abstractPiotr Ponikowski(Poland)
Presentation webcastPresentation slides
707005 - 707006
Hot Line II - Frontiers in interventional and device treatments
© 2017 European Society of Cardiology. All rights reserved